Hilton Capital Management’s AstraZeneca AZN Stock Holding History

Hilton Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.6M	Buy	73,991 +1,325	+2%	+$255K	1.1%	19
2025 Q4	$13.4M	Buy	72,666 +201	+0.3%	+$35.3K	1.01%	21
2025 Q3	$11.1M	Sell	72,465 -5,573	-7%	-$843K	0.9%	24
2025 Q2	$10.9M	Sell	78,038 -409	-0.5%	-$57.3K	0.87%	31
2025 Q1	$11.5M	Buy	78,447 +788	+1%	+$114K	0.98%	22
2024 Q4	$10.2M	Sell	77,659 -10,087	-11%	-$1.41M	0.88%	35
2024 Q3	$13.7M	Buy	87,746 +1,960	+2%	+$316K	1.06%	24
2024 Q2	$13.4M	Sell	85,786 -15,747	-16%	-$2.37M	1.13%	25
2024 Q1	$13.8M	Buy	101,533 +368	+0.4%	+$48.7K	1.23%	20
2023 Q4	$13.6M	Sell	101,165 -422	-0.4%	-$54.9K	1.46%	15
2023 Q3	$13.8M	Sell	101,587 -5,179	-5%	-$707K	1.83%	12
2023 Q2	$15.3M	Sell	106,766 -2,332	-2%	-$343K	1.84%	14
2023 Q1	$14.8M	Sell	109,098 -3,345	-3%	-$450K	1.94%	12
2022 Q4	$12.3M	Hold	112,443	–	–	1.62%	16
2022 Q3	$12.3M	Buy	112,443 +21,433	+24%	+$2.72M	1.62%	16
2022 Q2	$12M	Buy	91,010 +13,745	+18%	+$1.8M	1.48%	20
2022 Q1	$10.3M	Buy	+77,265	New	+$9.27M	1.1%	38

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Hilton Capital Management's AZN Position: Q1 2026 in Review

Hilton Capital Management increased its AstraZeneca (AZN) stake by 1.8% in Q1 2026, buying an estimated $255K and bringing the position to 73,991 shares worth $14.6M. The position accounts for 1.1% of the portfolio, ranked #19.

Hilton Capital Management first reported a position in AZN in Q1 2022 and has held it in 17 quarters since. The position peaked at $15.3M in Q2 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Hilton Capital Management held 73,991 shares of AstraZeneca worth $14.6M as of Q1 2026.
Hilton Capital Management bought 1,325 AstraZeneca shares in Q1 2026, an estimated $255K.
AstraZeneca made up 1.1% of Hilton Capital Management's portfolio in Q1 2026, its #19 holding.
Hilton Capital Management first reported a position in AstraZeneca in Q1 2022 and has held it in 17 quarters since.
Hilton Capital Management's AstraZeneca position peaked at $15.3M in Q2 2023.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Hilton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.